Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα Oliver H. Krämer 1 , Sylvia Müller, Marc Buchwald, Sigrid Reichardt and Thorsten Heinzel Institute of Biochemistry and Biophysics, University of Jena, Jena, Germany 1 Correspondence: Institute of Biochemistry and Biophysics, University of Jena, Philosophenweg 12, D-07743 Jena, Germany. E-mail: o.kraemer@uni-jena.de The chromosomal translocation products AML1-ETO and PML-RARα contribute to the pathogenesis of leukemias. Here, we demonstrate that both AML1-ETO and PML-RARα are degraded by the ubiquitin-proteasome system and that their turnover critically depends on the E2-conjugase UbcH8 and the E3-ligase SIAH-1. Contrary to its role in HDAC2 degradation, the E3-ligase RLIM does not target AML1-ETO and PML-RARα for ubiquitin-dependent elimination. RLIM rather is a substrate of SIAH-1, which indicates that these E3-ligases operate in a hierarchical order. Remarkably, proteasomal degradation of leukemia fusion proteins, in addition to the block of histone deacetylase (HDAC) enzymatic activity is a consequence of HDAC-inhibitor treatment. The former requires the induction of UbcH8 expression and each of these processes might be beneficial for leukemia treatment. Our observations shed light on the mechanism determining the interplay between E2-conjugases, E3-ligases, and their substrates and suggest a strategy for utilizing the ubiquitylation machinery in a therapeutic setting.—Krämer, O. H., Müller, S., Buchwald, M., Reichardt, S., Heinzel, T. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα. Key Words: proteasomal degradation • RLIM • Siah-1 • UbcH8 • HDAC-inhibitor VPA
End of preview. The entire article is 11 pages. To view the full-text, please rent this article to continue.
/lp/fed-of-american-socs-for-experimental-biology/mechanism-for-ubiquitylation-of-the-leukemia-fusion-proteins-aml1-eto-vCUq2KMBoZ
Welcome to DeepDyve! Rent Premier Research Articles and Save Up to 90%
Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARα
Krämer, Oliver H.; Müller, Sylvia; Buchwald, Marc; Reichardt, Sigrid; Heinzel, Thorsten
Follow The FASEB Journal
, Volume 22 (5): 1369
Fed of American Socs for Experimental Biology – May 1, 2008
More Info
More Like This Article
View All dataSource[]=actageo&dataSource[]=aspet&dataSource[]=aaos&dataSource[]=aacc&dataSource[]=aacr&dataSource[]=aea&dataSource[]=aip&dataSource[]=ajnr&dataSource[]=ams&dataSource[]=aps_physical&dataSource[]=appi_book&dataSource[]=appi_journal&dataSource[]=apha&dataSource[]=asip&dataSource[]=asm&dataSource[]=asn&dataSource[]=aspb&dataSource[]=avs&dataSource[]=annual_reviews&dataSource[]=arxiv&dataSource[]=acm&dataSource[]=berghahn&dataSource[]=cabi&dataSource[]=clinical_trials&dataSource[]=dailymed&dataSource[]=degruyter&dataSource[]=du_press&dataSource[]=esa&dataSource[]=eu_press&dataSource[]=elsevier&dataSource[]=emerald&dataSource[]=ejtr&dataSource[]=emea&dataSource[]=epo&dataSource[]=faseb&dataSource[]=gsa&dataSource[]=health_affairs&dataSource[]=hindawi&dataSource[]=imanager&dataSource[]=imedpub&dataSource[]=informa_healthcare&dataSource[]=informs&dataSource[]=iop&dataSource[]=iucr&dataSource[]=iospress&dataSource[]=jbjs&dataSource[]=leftcoast&dataSource[]=lu_press&dataSource[]=mesharpe&dataSource[]=mary_ann_liebert&dataSource[]=medline&dataSource[]=mit_press&dataSource[]=nature&dataSource[]=oxford&dataSource[]=pier_professional&dataSource[]=pnas&dataSource[]=portlandpress&dataSource[]=psyc_articles&dataSource[]=psyc_books&dataSource[]=psyc_critiques&dataSource[]=plos_journal&dataSource[]=pubmed_central&dataSource[]=rsna&dataSource[]=rockefeller&dataSource[]=rcn&dataSource[]=ria&dataSource[]=rsc&dataSource[]=sage&dataSource[]=spie&dataSource[]=springer_journal&dataSource[]=springer&dataSource[]=taylor_francis&dataSource[]=aps&dataSource[]=the_scientist&dataSource[]=uc_press&dataSource[]=uspto_abstract&dataSource[]=wiley&dataSource[]=pct
© 2012 DeepDyve, Inc. All rights reserved.
Terms of Service | Privacy Policy
